Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Fig. 3

PSA results for PHiD-CV 2+1 versus a no vaccination and b PCV13 2+1 vaccination programs. The “cost-effective” threshold was taken to be 3 × GDP per capita. GDP gross domestic product, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year, USD United States dollars

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us